Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (BrdiN66001-17-2-4055)
Received: 8 August 2019
Accepted: 10 July 2020
First Online: 13 August 2020
: D.L. and A.C. are named inventors on Patent application no. PCT/US2020/026264 filed by The Broad Institute to compositions and methods as described in this manuscript. J.M.K. has been a paid consultant for companies including Stempeutics, Sanofi, Celltex, LifeVaultBio, Gecko Biomedical, Alivio Therapeutics, Skintifique, Molecular Infusions, Landsdowne Labs, Takeda, Quthero, and Mesoblast (see: ExternalRef removed). J.M.K. is also an inventor on a patent that was licensed to Mesoblast. J.M.K. holds equity in Frequency Therapeutics, a company that has licensed IP generated by J.M.K. that may benefit financially if the IP is further validated. The interests of J.M.K. were reviewed and are subject to management plans overseen by his institution in accordance with their conflict of interest policies. All other authors declare no competing interests.